Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Moodys
Mallinckrodt
Baxter

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR "GERMA-MEDICA ""MG"""


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for "germa-medica ""mg"""

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00270829 ↗ Renal Effects of Intrarenal Nesiritide Terminated University of Maryland Phase 4 2005-12-01 The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
NCT00270829 ↗ Renal Effects of Intrarenal Nesiritide Terminated University of Maryland, Baltimore Phase 4 2005-12-01 The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
NCT01033630 ↗ Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen Completed Chinese University of Hong Kong Phase 2 2006-01-01 Atherosclerosis (in particular stroke and heart attack) is the most important health issue in modernized society and high blood pressure is an important predisposing factor. Hypertensive subjects with other chronic disease such as diabetes mellitus or impaired renal function are particularly vulnerable to these atherosclerotic complications in spite of standard antihypertensive therapies. Danshen and Gegen are commonly used in Chinese materia medica as treatment for cardiac symptoms and atherosclerosis-related disorders. The objective of this study is to test Danshen and Gegen as an cardiovascular-protective adjunctive regimen to prevent high-risk hypertensive cohort from primary atherosclerosis.
NCT01677247 ↗ Bioequivalence Study of 4 mg Glimepiride Tablet Completed Dexa Medica Group N/A 2011-02-01 This was a randomized, single blind, two-period, two sequence cross-over study under fasting condition to compare the bioavailability of two glimepiride 4 mg tablet formulations (test and reference formulations).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for "germa-medica ""mg"""

Condition Name

Condition Name for "germa-medica ""mg"""
Intervention Trials
Healthy 6
Small-cell Lung Cancer 2
Diabetes Mellitus 1
Sensitive Pulmonary Tuberculosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for "germa-medica ""mg"""
Intervention Trials
Small Cell Lung Carcinoma 2
Lung Neoplasms 2
Chikungunya Fever 1
Constipation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for "germa-medica ""mg"""

Trials by Country

Trials by Country for "germa-medica ""mg"""
Location Trials
China 8
Indonesia 7
Colombia 4
Italy 1
Panama 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for "germa-medica ""mg"""
Location Trials
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for "germa-medica ""mg"""

Clinical Trial Phase

Clinical Trial Phase for "germa-medica ""mg"""
Clinical Trial Phase Trials
Phase 4 3
Phase 2/Phase 3 3
Phase 2 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for "germa-medica ""mg"""
Clinical Trial Phase Trials
Completed 10
Recruiting 6
Unknown status 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for "germa-medica ""mg"""

Sponsor Name

Sponsor Name for "germa-medica ""mg"""
Sponsor Trials
Dexa Medica Group 7
Peking University First Hospital 2
Fundacion Cancer FUCA 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for "germa-medica ""mg"""
Sponsor Trials
Other 43
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Baxter
Harvard Business School
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.